Serina Therapeutics Stock Market Outlook
| SER Stock | 1.75 -0.06 -3.31% |
The sentiment reading measures how supportive or cautious recent coverage has been relative to its own baseline, which can help explain market framing without replacing valuation or risk analysis. Around 62% of recent sentiment around Serina Therapeutics has leaned defensive over the recent sample. Taken on its own, that leaves Current sentiment reading for Serina Therapeutics below neutral right now.
Investor Comfort Level
PanicConfidence
38 · Alarmed
Elasticity to Hype and News Sentiment
Serina Therapeutics news sentiment reading of 50% (mixed) tracks how media and analyst commentary are framing the investment case. Shifts in news tone at this level often precede a change in trading character that warrants attention.
Over a 90-day investment horizon, with a moderate risk tolerance, the model output for Serina Therapeutics is 'Strong Sell'. The Serina Therapeutics buy-or-sell recommendation is derived from the selected investment horizon and risk tolerance parameters for Serina Therapeutics.
Serina |
Run Serina Therapeutics Outlook Model
Our Serina outlook module adds a quantitative perspective alongside analyst views on Serina Therapeutics. Macroaxis carries no residual or financial interest in Serina Therapeutics or related securities.
How This Model Works
The recommendation output for Serina Therapeutics is a model-based view that converts the selected horizon and risk profile into a standardized reading of the current evidence.
- Inputs - valuation signals, price behavior, volatility, liquidity, sentiment, and analyst coverage when available
- Current setup - Three Months with a risk setting described as I am an average risk taker
- Limits - the model does not account for taxes, outside holdings, concentration constraints, or investor-specific mandates
Use the output as structured decision support and pair it with your own research, portfolio context, and any professional advice you rely on.
Time Horizon
Risk Tolerance
Strong Sell
Market Performance | Soft | Details | |
Volatility | Abnormal | Details | |
Current Valuation | Above Model Estimate | Details | |
Odds Of Distress | Below Average | Details | |
Economic Sensitivity | Actively responds to the market | Details | |
Investor Sentiment | Alarmed | Details | |
Analyst Consensus | Not Available | Details | |
Financial Leverage | Not Rated | Details | |
Reporting Quality (M-Score) | Unavailable | Details |
Serina Therapeutics' current outlook reflects a cautious setup, where recent market performance has undercut momentum, while contained volatility and intact fundamental quality provide partial offset. The model's 'Strong Sell' signal reflects persistent headwinds that outweigh the offsetting factors in the model. For the selected horizon, Serina Therapeutics yields Mean Deviation of 6.71, Standard Deviation of 14.0, and Variance of 195.96, which weigh on the current risk-reward outlook.Serina Therapeutics' analytical framework reflects a quantitative assessment of growth potential, downside exposure, and market positioning relative to the analyst sentiment. For additional context on this micro-cap stock in the Health Care sector, assess the full set of Serina Therapeutics reported fundamentals, including the relationship between the short ratio ttm and market capitalization ttm. Given Serina Therapeutics' number of shares shorted reading, its fundamentals and Probability Of Bankruptcy provide additional context for this model output.
Recent Events and Market Context
The events below reflect recent headlines associated with Serina Therapeutics. Not all items directly affect the outlook — they are included to show the broader information environment that can shape sentiment and trading behavior.
Returns Distribution Density
The return distribution below plots how often Serina Therapeutics has posted different daily returns. Tighter clustering means more predictable returns, while wider spread means more surprise.
| Mean Return | -0.0097 | Value At Risk | -13.03 | Potential Upside | 9.28 | Standard Deviation | 14.00 |
Return Density |
| Distribution |
Managing risk starts with understanding how wide Serina Therapeutics' price swings have been historically. This is the starting point for sound risk management of Serina Therapeutics.
Key Drivers of Volatility and Market Exposure
Serina Therapeutics carries exposure to broad market movements as well as company or sector-specific developments. While portfolio diversification can reduce asset-level risk, systematic volatility cannot be avoided. Standard deviation and beta quantify this exposure. Serina Therapeutics (SER) recorded a Mean Deviation of 6.71 and a Standard Deviation of 14.00.
α | Alpha over Dow Jones | -0.016 | |
β | Beta against Dow Jones | 1.72 | |
σ | Overall volatility | 14.10 | |
Ir | Information ratio | -0.0013 |
Fundamentals Vs Peers
Peer comparison anchors Serina Therapeutics' financial performance to a concrete reference point rather than abstract benchmarks. Serina Therapeutics' competitive standing becomes clear when margins, returns, and leverage are measured against comparable stocks.
| Better Than Average | Worse Than Average | Compare Serina Therapeutics to competition |
| Fundamentals | Serina Therapeutics | Peer Average |
| Return On Equity TTM | -81.59 | -0.31 |
| Return On Asset TTM | -2.2 | -0.14 |
| Operating Margin TTM | -184.78 | -5.51 |
| Current Valuation | 31.61 M | 16.62 billion |
| Shares Outstanding | 14.9 M | 571.82 million |
| Shares Owned By Insiders | 34.30 % | 10.09 % |
| Shares Owned By Institutions | 9.52 % | 39.21 % |
| Number Of Shares Shorted | 373.66 K | 4.71 million |
| Price To Book TTM | 12.18 X | 9.51 X |
| Price To Sales TTM | 207.43 X | 11.42 X |
| Revenue TTM | 130 K | 9.43 billion |
| Gross Profit TTM | -13.03 M | 27.38 billion |
| EBITDA TTM | -24.02 M | 3.9 billion |
| Net Income TTM | -19.44 M | 570.98 million |
| Cash And Equivalents TTM | 3.06 M | 2.7 billion |
| Total Debt TTM | 196 K | 5.32 billion |
| Book Value Per Share TTM | -0.46 X | 1,931 |
| Cash Flow From Operations TTM | -17.95 M | 971.22 million |
| Short Ratio TTM | 0.04 X | 4.00 X |
| Earnings Per Share | -1.91 X | 3.12 X |
| Target Price | 11.0 | N/A |
| Number Of Employees | 12 | 18,840 |
| Trailing Beta | 0.039 | -0.15 |
| Market Capitalization TTM | 26.97 M | 19.03 billion |
| Total Asset TTM | 6.95 M | 29.47 billion |
| Retained Earnings TTM | -63.5 M | 9.33 billion |
| Working Capital TTM | 2.52 M | 1.48 billion |
| Net Asset | 6.95 M | N/A |
Note: Disposition of 4326 shares by Moreadith Randall of Serina Therapeutics at 0.06 subject to Rule 16 b-3 [view details]
Market Momentum
Beta of 1.7157 amplifies broad market moves. Serina Therapeutics strength readings help frame whether the current move is gaining support or losing conviction. Comparing Serina Therapeutics strength readings with sector peers helps distinguish stock-specific momentum from broad rotation.
Recommendation Framework, Assumptions & Editorial Oversight
The model output for Serina Therapeutics reflects the current horizon and risk settings, refreshes as underlying data changes, and is intended to organize evidence rather than replace investor judgment. Current model inputs for Serina Therapeutics include ROE of -81.59%, market cap of 26.97 million. 
Serina Therapeutics inputs come from periodic company reporting and market reference feeds and are mapped into a consistent reporting framework. The model combines valuation, price behavior, volatility, and sentiment into a standardized quantitative view.
Editorial Review & Methodology Oversight
Role: Member of Macroaxis Editorial Board
Finance background: Rifka covers equity valuation and corporate fundamentals across technology, consumer, and service sectors. Her analysis focuses on margin structure, capital allocation, and governance practices.
Oversight scope: Reviews recommendation-framework framing, source assumptions, and disclosure language.